Organovo closes FXR program sale to Lilly; expects reduced spend and runway into FY2026

VivoSim Labs, INC.

FXR program sold to Lilly; upfront payments received with future milestone payments anticipated.
Overall expenditures expected to decrease due to elimination of FXR-related clinical, regulatory, and IP costs.
Cash runway projected through end of FY2026; additional milestone payments could extend runway.
Plans to leverage 3D human cellular IBD models to replicate FXR success with another therapeutic opportunity.
Full-year FY2025 financial results expected on or about June 6-10, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.